AbbVie Reports Third-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Abbvie (ABBV) PT Lowered to $71 at BMO Capital
November 5, 2018 8:47 AM ESTBMO Capital analyst Alex Arfaei lowered the price target on Abbvie (NYSE: ABBV) to $71.00 (from $78.00) while maintaining a Underperform rating.
The analyst commented, "3Q18 was fine, but not great; particularly the Imbruvica beat. The market is ignoring management's long-term guidance, and signals of... More
AbbVie (ABBV) Tops Q3 EPS by 12c, Lifts FY EPS Guidance
November 2, 2018 7:48 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $2.14, $0.12 better than the analyst estimate of $2.02. Revenue for the quarter came in at $8.24 billion versus the consensus estimate of $8.22 billion.
GUIDANCE:
AbbVie sees Q4 2018 EPS of $7.90-$7.92, versus the consensus of $7.88.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More